Tempus AI, Inc.
corporate_fare Company Profile
Tempus AI, Inc. (NASDAQ:TEM) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 30 items for TEM at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-11, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 16 rated 8 or above. Recent SEC coverage for TEM spans S-4, 144, 10-Q, 8-K.
Recent high-impact activity:
- Tempus AI Targets 100K Whole-Genome Dataset to Power AI Drug Discovery
- Tempus AI Files S-4 for $1.5B Personalis Acquisition — Exchange Ratio, Cash Election, and Regulatory Timeline Detailed
- Tempus AI Founder Eric Lefkofsky Files to Sell $16.5M in Stock
- Tempus AI Wins FDA Clearance for AI Tool That Flags Pulmonary Hypertension From ECGs
- Merck-Moderna Phase 3 Win Validates Tempus AI's Personalis Bet, Stock Jumps 18%
Financial Snapshot
Dilution Risk
Low riskFiling-implied dilution signals for TEM, detected from its recent SEC filings · based on capital-structure filings through 2026-05-12.
Completed $460M Convertible Notes Offering · Favorable Pricing Terms
⚠ A more recent filing has been published for this ticker since this signal was computed; it may not yet be reflected — see the filings below.
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →